Insomnia News and Research

Latest Insomnia News and Research

Simple interventions could reduce delirium and improve patient perceptions about sleep quality

A hospital is not the best place to get a good night's sleep, especially in a noisy intensive care unit. It's a cause for concern because studies have shown that a lack of sleep can cause patients to experience delirium-an altered mental state that may delay their recovery and lead to short and long-term confusion and memory problems.

21 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

Nightmare of insomnia could explain suicide link in patients with depression

The link between insomnia and suicidal thoughts in patients with depression may be mediated by nightmares and dysfunctional beliefs and attitudes about sleep, research suggests.

15 Feb 2013

Study discovers new predictor for suicidal thinking

When people lose hope that they will ever get another good night's sleep, they become at high risk for suicide, researchers report.

15 Feb 2013

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2012.

9 Feb 2013

Older adults with COPD more frequently use benzodiazepines

A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

9 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Sleep disorders common in active duty military personnel

Researchers have found significant associations between service-related illnesses and a high rate of sleep disorders, particularly insomnia, in US military personnel.

4 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Noninvasive, drugless therapy may help mitigate symptoms associated with neurological conditions

With the infusion of an additional $1 million of financial support from The Susanne Marcus Collins Foundation, Inc., Atlanta, GA, Wake Forest Baptist Medical Center researchers are expanding their studies using a noninvasive, drugless therapy that may help to mitigate symptoms associated with a list of neurological conditions.

30 Jan 2013

Sleep duration naturally waxes and wanes according to researchers at University of Sydney

There’s no need to panic if you didn’t get a solid eight hours of beauty sleep last night. According to new University of Sydney research, sleep duration naturally waxes and wanes over a period of days regardless of individual lifestyle, timing of sleep or waking, and social and environmental influences.

29 Jan 2013

Transcendental Meditation technique reduces PTSD symptoms in U.S. Marines

U.S. Marines and other active-duty military personnel who suffer from post-traumatic stress disorder (PTSD) are finding relief through a simple meditation technique known as the Transcendental Meditation (TM) technique.

29 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Medical cannabis can improve appetite, ease chronic pain, say researchers

Though controversial, medical cannabis has been gaining ground as a valid therapy, offering relief to suffers of diseases such as cancer, Post-Traumatic Stress Disorder, ALS and more.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Trial to evaluate whether zolpidem reduces suicidal thinking in depressed insomniacs

Researchers want to know whether a sleeping pill reduces suicidal thoughts in depressed patients with insomnia.

23 Jan 2013

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

UC Irvine-led studies have revealed the cellular mechanism by which circadian rhythms - also known as the body clock - modify energy metabolism and also have identified novel compounds that control this action. The findings point to potential treatments for disorders triggered by circadian rhythm dysfunction, ranging from insomnia and obesity to diabetes and cancer.

23 Jan 2013

Daytime insomnia impact varies by subtype

Insomnia’s daytime impact appears to be greatest among those patients who have trouble both initiating and maintaining sleep, those with poor mental health, and those with childhood onset of the disorder, findings from the Great British Sleep Survey suggest.

14 Jan 2013

FDA requires sleep drugs that contain zolpidem to lower recommended doses

The U.S. Food and Drug Administration today announced it is requiring the manufacturers of Ambien, Ambien CR, Edluar and Zolpimist, widely used sleep drugs that contain the active ingredient zolpidem, to lower current recommended doses. Ambien and Ambien CR are also available as generics.

11 Jan 2013

Virtual patient can help future physicians more comfortable and capable assessing suicide risk

A virtual patient named Denise may help future physicians feel more comfortable and capable assessing suicide risk.

7 Jan 2013

Insomnia News and Research

Latest Insomnia News and Research

Simple interventions could reduce delirium and improve patient perceptions about sleep quality

Positive results from Neurim’s Piromelatine phase II study on insomnia

Nightmare of insomnia could explain suicide link in patients with depression

Study discovers new predictor for suicidal thinking

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Older adults with COPD more frequently use benzodiazepines

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Sleep disorders common in active duty military personnel

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Noninvasive, drugless therapy may help mitigate symptoms associated with neurological conditions

Sleep duration naturally waxes and wanes according to researchers at University of Sydney

Transcendental Meditation technique reduces PTSD symptoms in U.S. Marines

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Medical cannabis can improve appetite, ease chronic pain, say researchers

Neuromuscular blockade (NMB) reversal

Trial to evaluate whether zolpidem reduces suicidal thinking in depressed insomniacs

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

Daytime insomnia impact varies by subtype

FDA requires sleep drugs that contain zolpidem to lower recommended doses

Virtual patient can help future physicians more comfortable and capable assessing suicide risk

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Insomnia News and Research

Latest Insomnia News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in